Fig. 2

Treatment recommendations for case 1, a high-risk oligodendroglial LGG, in 12/2016 (left panel) and 2015 (right panel). After publication of the final results from RTOG 9802 and in comparison to 2015, patients with oligodendroglial LGGs were more likely to receive active treatments (89% vs. 76%), predominantly with radiotherapy followed by chemotherapy with PCV (61% vs. 31%)